FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...
Business Insider11h
Cautious Optimism for Novavax Amid Clinical Hold Challenges
Jefferies analyst Roger Song has maintained their bullish stance on NVAX stock, giving a Buy rating on October 10. Roger Song has given his Buy rating due to a combination of factors that, despite ...
SchaeffersResearch.com4h
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
Novavax Shares Plummet as FDA Pauses Key Vaccine Trials Amid Safety Concern
A single adverse event halts trials for Novavax's COVID-19 and influenza combination vaccine, raising concerns but leaving ...
FDA Puts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Tumbles
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza ...
Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine
Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse ...
bovnews2d
Why Did Novavax Inc (NVAX) Stock See -17.13% Plunge in the Last 90 Days?
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.53 which represents a decrease of $-0.37 or -2.87% from the prior close of $12.9. The stock opened at $12.72 and touched a low ...
Nasdaq6d
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
Finanznachrichten5h
Novavax, Inc.: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that the U.S. Food and ...
ETF Daily News6d
Novavax (NASDAQ:NVAX) Stock Price Up 3.4% – Still a Buy?
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) shot up 3.4% during mid-day trading on Tuesday . The company traded as high as $13.54 and last traded at $13.46. 1,167,174 shares traded ...
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...